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Abstract: Nuclear factor κB (NF-κB) is a well-known pro-inflammatory transcription factor that 
regulates the expression of the tissue’s immune-active components, which include cytokines, 
chemokines and adhesion molecules. In addition, the versatile nuclear factor of activated  
T-cells (NFAT) family of transcription factors plays a crucial role in the development and function 
of the immune system, integrating calcium signaling with other signaling pathways. NF-κB and 
NFAT share many structural and functional characteristics and likely regulate gene expression 
through shared enhancer elements. This review describes recent research data that has led to new 
insights into the involvement of NFκB- and NFAT-mediated pathways in the different idiopathic 
inflammatory myopathies. The general activation of NF-κB p65 in blood vessel endothelium, seems 
to flag down inflammatory cells that subsequently accumulate mostly at perimysial sites in 
dermatomyositis. The joint activation of p65 and NFAT5 in myofibers specifically at perifascicular 
areas reflects the characteristic tissue damage pattern observed in that particular subgroup of patients. 
In immune cells actively invading nonnecrotic muscle fibers in polymyositis and sporadic inclusion 
body myositis on the other hand, p65 activation is an important aspect of their cytotoxic and 
chemoattactant properties. In addition, both transcription factor families are generally upregulated in 
regenerating muscle fibers as components of the differentiation process. It can be concluded that the 
two transcription factor families function in close relationship with each other, representing two-
edged swords for muscle disease: on the one hand promoting cell growth and regeneration, while on 
the other hand actively participating in inflammatory cell damage. In this respect, cytokines function 
as important go-betweens at the crossroads of the pathways. Beyond NF-κB and NFAT, many 
fascinating winding roads relevant to inflammatory myopathy disease management still lie ready for 
the exploring. 
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Abbreviations 
AKR1B1     Aldose reductase 
DM       Dermatomyositis 
IIM       Idiopathic inflammatory myopathies 
IMNM      Immune-mediated necrotizing myopathy 
iNOS      Inducible nitric oxide synthase  
IκB       Inhibitor κB 
IKK      IκB kinase  
LT-β      Lymphotoxin β 
MCP-1      Monocyte chemoattractant protein 1 
NF-κB      Nuclear factor κB 
NFAT      Nuclear factor of activated T-cells 
PM       Polymyositis 
SLC5A3      Sodium/myo-inositol cotransporter 
IBM      Sporadic inclusion body myositis 
SLC6A6      Taurine transporter 
TNF-α      Tumor necrosis factor α 
 
1. Introduction 
Chronic inflammation of skeletal muscle tissues, termed myositis, can have various origins. It 
can result from infection, tissue damage caused by inherited disorders, or an acquired autoimmune 
disease. In the muscular dystrophies for instance, muscle inflammation is secondary to tissue damage 
caused by deficiency of the dystrophin complex, yet represents an important pathogenic factor that 
contributes substantially to tissue deterioration [1]. In this review, focus will be on the involvement 
of pro-inflammatory transcription factors in the idiopathic inflammatory myopathies (IIM). The IIM 
comprise four main entities: dermatomyositis (DM), polymyositis (PM), sporadic inclusion body 
myositis (IBM), and immune-mediated necrotizing myopathy (IMNM). Each of these disease 
subgroups presents with distinct clinical and myopathological characteristics, with either the blood 
vessels or the muscle fibers as preferential immune-target. In DM, complement-mediated blood 
vessel destruction and perifascicular inflammation develop. PM and IBM are characterized by 
cytotoxic attack of nonnecrotic muscle fibers and mostly endomysial buildup of inflammation [2]. In 
IBM muscle fibers, additional degenerative phenomena occur, with rimmed vacuoles and inclusions 
that contain ectopic proteins [3]. IMNM is an increasingly recognized autoimmune myopathy, in 
subgroups of patients triggered by statin use and associated with autoantibodies directed against  
3-hydroxy-3-methylglutaryl-coenzymeA reductase [4].  
In the IIM, progressive muscle damage is caused by an autoimmune response to skeletal 
muscle-derived antigens [5], yet many of the immunopathogenic processes underlying the diseases 
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remain poorly understood until today. It is, however, generally accepted that muscle fibers are active 
participants and that the interaction between immune cells, blood vessel endothelial cells and muscle 
fibers is requisite to the sustained inflammatory response.  
2. NF-κB and Inflammatory Myopathies 
Nuclear factor κB (NF-κB) is a ubiquitous yet inducible transcription factor and a key organizer 
of inflammatory processes. The transcription factor is encoded by a multigene family (Table 1). 
Functional NF-κB is a dimer that can be composed of different sets of subunits, with the most 
common cytoplasmic form of NF-κB a heterodimer composed of p50 and p65 subunits. Individual 
NF-κB dimers acquire different transcriptional properties and can recognize slightly different DNA 
targets.  
Table 1. NF-κB and NFAT transcription factor families and their involvement in 
inflammatory myopathies. 
 Subunits/subforms/names Expression in IIM 
NF-κB p105-p50/NFκB1 Increased in blood vessels and muscle fibers, and 
expressed by infiltrating inflammatory cells 
 p100-p52/NFκB2 Unknown 
 p65/RelA Increased and activated in blood vessels and muscle 
fibers, and expressed by infiltrating inflammatory cells 
 cRel Unknown 
 RelB Unknown 
NFAT NFAT1/NFATc2/NFATp Unknown 
 NFAT2/NFATc1/NFATc Unknown 
 NFAT3/NFATc4 Unknown 
 NFAT4/NFATc3/NFATx Unknown 
 NFAT5/NFATz/NFATL1/TonEBP/CREBP Increased and activated in muscle fibers 
In most resting cells, NF-κB is retained in the cytosol in an inactive form sequestered through 
interaction with its inhibitor κB (IκB). Its major activation pathway starts with stimulation of the IκB 
kinase (IKK), which leads to IκB phosphorylation and subsequent proteosomal degradation of the 
inhibitor. Additional post-translational modifications of NF-κB subunits regulate the transcription 
factor’s transactivation potential and includes phosphorylation of serine and threonine residues, with 
phosphorylation of the p65 subunit’s Ser276, Ser468 and Ser536 residues as the best studied [6]. 
The importance of NF-κB pathways in human inflammatory diseases has long been recognized 
and cannot be overestimated. The transcription factor is indeed a key mediator of pro-inflammatory 
gene expression in the IIM, but is also involved in muscle tissue maintenance, regulating cell 
proliferation and differentiation. Under normal conditions, NF-κB activation is a transient process, 
which is stopped by IκB entering the nucleus, dislodging NF-κB from its DNA binding sites. In 
chronic inflammatory states however, which includes IIM, activation is sustained and transcription of 
responsive genes is continuously initiated. Myopathological data firmly corroborates an increased 
NF-κB transcriptional activity in the IIM. NF-κB-electrophoretic mobility shift assays reveal that 
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NF-κB-DNA binding activity is variably but consistently increased in DM/PM/IBM compared to 
control muscle [7,8]. 
Several studies are available typing NF-κB subunits p50/p65 in the different IIM, and have been 
reviewed in [9]. Protein levels of p65 are significantly increased in muscle tissue samples of DM, 
PM and IBM patients [8,10], and it can be concluded that p50/p65 activation is a more general 
phenomenon present in the IIM irrespective of patient subtyping. Genetic predisposition related to 
NF-κB could however not be observed. A study of 63 single nucleotide polymorphisms from NF-κB-
related genes showed that NF-κB genes do not confer susceptibility to DM/PM [11]. 
Muscle fibers constitutively contain NF-κB subunits p50 and p65, but studies indicate their 
activation in the IIM. In PM and IBM sections, phosphorylated active p65 is found within the 
myonuclei, a pattern not observed in control tissues [8]. Activated p65 staining is also increased in 
the atrophic fibers at perifascicular sites of DM and scattered atrophic fibers in PM/IBM/IMNM 
tissues [12]. Necrotic fibers in IIM tissues are most often p50 and p65 positive, with only part 
staining for phosphorylated p65 [12,13]. The large majority of vacuolated fibers in IBM tissues 
contain p50 and p65 positive inclusions [13], with activated p65 observed in part of the vacuolated 
fibers [7,13]. This NF-κB activation may result in the endoplasmic reticulum overload response 
characteristic of IBM fibers, generating a self-sustained loop of cytokine release and amyloid 
precursor protein production [14]. This further illustrates how, in the IIM, muscle fibers are active 
participants in their own demise. They acquire major histocompatibility complexes on the 
sarcolemma [15], enabling them to present antigen to tissue-infiltrating immune cells. By producing 
various inflammatory factors, including adhesion molecules and cytokines, they mark themselves 
and their microenvironment as sites for autoimmune attack. As key regulator of pro-inflammatory 
gene expression, the pathological role of NF-κB activation in the muscle damage associated with IIM 
seems obvious. However, adding nuance to the culpabilization of the transcription factor, p65 and 
p50 are also induced in the regenerating muscle fibers within patient tissues [7,9], indicating a 
potentially protective role in myogenesis and repair is also at play. 
DM is a systemic disease associated with blood vessel damage within the skeletal muscle tissue. 
The autoimmune response specifically targets the blood vessel endothelium, a process in which 
complement deposition is an early event [16]. The trigger that initiates complement activation still 
remains unclear. Further along, the affected blood vessels express a broad range of pro-inflammatory 
mediators, including adhesion molecules, cytokines and chemokines, attracting circulating 
monocytes and lymphocytes. The distribution of NF-κB reflects this particular endotheliopathic 
nature of DM. Generally enhanced expression of p65 and p50 can be observed in DM blood vessel 
endothelium, often with strong staining for phosphorylated p65 (Figure 1A). In PM/IBM, blood 
vessel p65 upregulation occurs more rarely [17]. It thus seems that endothelial NF-κB activation and 
subsequent expression of pro-inflammatory factors plays a pivotal role in the accumulation of 
perivascular inflammatory infiltrates in DM tissues in particular. 
Inflammatory cells infiltrating IIM tissues broadly express p50 and p65, with part of muscle-
infiltrating T-cells, B-cells, and macrophages of both the auto-aggressive M1 and regenerative M2 
lineages, being positive [12,17]. Subsets also stain for phosphorylated p65 (Figure 1A–C). In 
immune cells actively invading nonnecrotic muscle fibers of PM/IBM tissues, most often cytotoxic 
T-cells or M1 macrophages, the activated form of p65 can be detected most frequently [12]. It can 
therefore be concluded that NF-κB activation is an important aspect of the cytotoxicity displayed by 
inflammatory cells infiltrating IIM muscle. 
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Figure 1. Immunofluorescent staining for NF-κB subunit p65 and NFAT5 in 
dermatomyositis muscle. (A–C): A subset of muscle fibers acquire sarcoplasmic Ser536 
phosphorylated p65 staining (CY3, red), part of which are small regenerating or atrophic 
muscle fibers. Blood vessel endothelium is strongly positive (asterisk) and part of 
CD206+ (AlexaFluor488, green) M2 macrophages, both cells infiltrating necrotic muscle 
fibers (upper arrowhead) and interstitial cells (lower arrowhead), are positive. (D–F): 
Myonuclei stain strongly for NFAT5 (CY3, red) throughout the tissues, but perifascicular 
small muscle fibers acquire additional sarcoplasmic staining. In these regenerating or 
atrophic perifascicular muscle fibers, Heat Shock Protein 70 staining (AlexaFluor488, 
green) is concomitantly increased. Antibodies used: rabbit polyclonal anti-Ser536 
phosphorylated p65, SantaCruz Biotechnology, 1 µg/ml; mouse monoclonal anti-CD206, 
Dako, 6.6 µg/ml; rabbit polyclonal anti-NFAT5, Acris, 20 µg/ml; mouse monoclonal 
anti-HSP70, Chemicon, 1/100 dilution. Scale bar = 50 µM. 
3. NFAT and Inflammatory Myopathies 
The Nuclear factor of activated T-cells (NFAT) transcription factor family, contains five 
members (Table 1) that are expressed in most cells of the immune system. In T-cells, NFAT proteins 
not only regulate activation but are also involved in cell differentiation and self-tolerance. These 
transcription factors possess, however, a much broader expression pattern, spanning many different 
cell types. NFAT regulate tissue development, including the buildup of skeletal muscle. The 
functional versatility of NFAT proteins can be explained by their complex mechanism of regulation 
and their ability to integrate calcium-regulated processes with other signaling pathways. 
In the cytoplasm of resting cells, NFAT1-4 proteins are phosphorylated, and their nuclear 
import is opposed by maintenance kinases. In response to calcium signaling, they interact with 
calcineurin, a cytoplasmic phosphatase, which removes phosphates from multiple protein sites. 
Dephosphorylation of serine residues exposes the NFAT nuclear-localization signal and leads to 
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translocation of the transcription factor to the nucleus, that thus becomes transcriptionally active. In 
addition, the corresponding nucleus’ export kinases become inactivated to achieve NFAT nuclear 
retention [18]. The fifth family member NFAT5 is differentially regulated. It is not stimulated by 
calcium, but activated by increased sodium concentrations, with hyperosmotic conditions inducing 
phosphorylation of the carboxy-terminal transactivation domain. NFAT5 is constitutively nuclear in 
many cell types [19]. 
Skeletal muscle can potentially express all isoforms, and NFAT regulate the transcription of a 
variety of muscle specific genes involved in skeletal muscle development and differentiation. 
NFAT2 is a key mediator of activity-dependent transcriptome regulation, with disuse reducing the 
NFAT2 content of the myonuclei [20]. Anabolic steroids activate calcineurin/NFAT signaling, with 
increased nuclear levels of NFAT3, resulting in hypertrophy in cultured myotubes and protection 
against denervation atrophy in rats [21]. For the control of fiber type distribution, the NFAT family 
also seems crucial. Type I or slow twitch muscle fibers utilize oxidative metabolism and are fatigue 
resistant, while type II or fast twitch fibers utilize glycolytic metabolism and fatigue rapidly. NFAT1 
and NFAT4 are closely associated with the expression of fast twitch myofibrillar proteins [22], while 
NFAT2 induces slow twitch genes. NFAT are important regulators of myogenesis, and individual 
family members are activated only at specific stages [23], allowing them to regulate distinct subsets 
of genes. It appears also that different transcription factors display distinct co-activator/co-repressor 
interactions. NFAT2 has a negative influence on MyoD, the central regulator of the differentiation of 
myoblasts into functional multinucleate myotubes, whereas NFAT4 cannot block MyoD activity [24]. 
In damaged rat muscle, calcineurin and NFAT2 interact, and levels of activated NFAT2 are 
markedly increased in the first days after injury, gradually returning back to baseline levels [25]. 
NFAT5 levels are also increased in the regenerating fibers of mice exposed to experimental muscle 
tissue injury [26]. 
Despite their obvious involvement in muscle physiology, sparse data is currently available 
regarding the involvement of NFAT in the IIM, with only NFAT5 having been studied in some detail. 
The prominent myonuclear NFAT5 expression present in healthy skeletal muscle is increased further 
in IIM. In DM muscle, additional sarcoplasmic staining can be observed which is restricted mostly to 
perifascicular areas (Figure 1D). Possibly this changed intracellular expression pattern represents a 
regulatory mechanism, adjusting NFAT5 activity to the atrophic processes that in DM typically 
unfurl at the periphery of the muscle fascicle. An extra clue is that, in these perifascicular atrophic 
muscle fibers of DM muscle, otherwise absent staining for Ser1197 phosphorylated NFAT5 becomes 
prominent [10]. The precise role of this particular serine phosphorylation has not been elucidated in 
full, but phosphorylation appears to contribute to the protein’s stability and activity in response to 
stress. In arterial smooth muscle cells, an NFAT5 increase and Ser1197 phosphorylation is observed 
in response to biomechanical stretch [27]. 
NFAT5 staining of part of blood vessels can be observed, which is no different from that in 
healthy control muscle. In arterial smooth muscle cells [27] as well as in endothelial cells [28], basal 
levels of NFAT5 are present, and expression promotes angiogenic processes. 
So far, expression of NFAT5 could not be observed in the immune cells infiltrating the IIM 
muscle tissue [10]. This lack of immunoreactivity is somewhat surprising and could be due to 
technical reasons, variation of expression levels in different activation states and/or transient 
expression patterns that subside once immune cells penetrate the muscle tissue. 
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4. NF-κB and NFAT5 Interactions in Inflammatory Myopathies 
The NF-κB and NFAT transcription factor families clearly are evolutionarily related. 
Respective promoter binding sites, κB for NF-κB and osmotic response elements or TonE for 
NFAT5, closely resemble one another. NFAT5 in particular can thus be regarded as a cousin within 
the subgroup of the large family of Rel/NF-κB proteins. Similar to NF-κB and unlike other NFAT 
family members, NFAT5 binds DNA as an obligate homodimer [29]. It is known that p50 and p65 
can bind and activate TonE elements, and vice versa, hypertonicity promotes nuclear translocation 
and increases NF-κB activity. It is also known that NFAT proteins have weak DNA-binding capacity, 
achieving effective binding through cooperation with other nuclear resident transcription factors. In 
this story of cooperative binding, NF-κB could well be their privileged partner. Binding of  
p65-NFAT5 complexes to κB elements of NF-κB-responsive genes has been reported [30]. These 
authors propose a mechanism of interaction between NF-κB and NFAT5 mediated by mitogen-
activated protein kinases and protein kinase B activation. Also, physical interactions between 
NFAT2 and NF-κB subunits cRel [31] and p65 [32] have been documented, the latter promoting 
proliferation of cardiomyocytes. 
In IIM NF-κB and NFAT5 signaling pathways seem indeed to be closely connected. In the 
perifascicular atrophic fibers of DM muscle in particular, p65 and NFAT5 staining and activation 
coincide [10], linking these pathways in this important pathological hallmark. Several pro-
inflammatory mediators seem to act as important go-between in the communication between the two 
pathways. It is well known that NF-κB controls the expression of pro-inflammatory cytokines, by 
binding κB elements in their promoter regions. In addition, NFAT-regulated gene expression is an 
early event in lymphocyte activation following antigen-receptor-binding [33] and stimulates 
adhesion molecule and cytokine expression. Several genes involved in inflammatory processes share 
NFAT5 and NF-κB activation (Table 2). Importantly, NFAT5 is known to control the expression of 
tumor necrosis factor α (TNF-α), lymphotoxin β (LT-β) and monocyte chemoattractant  
protein 1 (MCP-1) genes, which all three happen to be key cytokines involved in the 
immunopathogenesis of IIM [34,35,36]. 
Table 2. Genes with documented combined NF-κB and NFAT5 transcription factor 
sensitivity. 
Cytokines Osmolyte accumulators 
Tumor necrosis factor alpha (TNF-α) Aldose reductase (AKR1B1) 
Lymphotoxin β (LT-β) Aquaporin 2 
Monocyte chemoattractant factor-1 (MCP-1) (CCL2) sodium/myo-inositol cotransporter (SLC5A3) 
Chaperones Cytotoxic factors 
Heat shock protein family of 70 kd (HSP70) Inducible NO synthase (iNOS) 
4.1. Tumor necrosis factor α 
The potent pro-inflammatory cytokine TNF-α plays a critical role in the immune responses that 
lead to the sustained inflammation characterizing the IIM, as reviewed in [34]. The TNF-α promoter 
contains binding sites for both NF-κB and NFAT family members, and expression is regulated in a 
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cell-type- and stimulus-dependent manner. NFAT1 and NFAT5 possess affinity to distinct TNF-α 
promoter sites, allowing the latter to specifically stimulate expression in response to hypertonic 
conditions [37]. NFAT5 binding to the TNF-α promoter has been shown in osmotically stressed  
T-cells [19]. In macrophages, NFAT5 promotes the M1 phenotype characterized by cytotoxic 
activities, through induction of inducible nitric oxide synthase (iNOS) and TNF-α gene expression, 
and suppresses the M2 phenotype and anti-inflammatory IL-10 gene expression [38]. iNOS 
immunoreactivity is most prominent in M1 macrophages actively invading nonnecrotic muscle fibers 
in PM/IBM tissues [39]. This raises the possibility of applying therapeutic strategies that selectively 
suppress this M1 activation, and this mode of action has already been put forward as an attractive 
strategy to combat inflammatory disease in general. Targeting CD64 for example, a high affinity 
IgG-binding receptor specifically overexpressed on M1 macrophages has proven to be an effective 
therapeutic target [40]. 
4.2. Lymphotoxin β 
LT-β also belongs to the TNF-superfamily of cytokines, and is a key factor in the organization 
of immune cells into tertiary lymphoid organs. Especially in DM, organization of T-cells, dendritic 
cells and B-cells into follicle-like collections localized within the muscle tissue, can often be 
observed and puts LT-β forward as a possible regulator. In the IIM, LT-β is indeed expressed by 
subsets of inflammatory cells and by regenerating and necrotic muscle fibers. In addition, LT-β 
expression by muscle fibers of normal width appears to be an early event that precedes 
inflammation-induced tissue damage [35], putting the cytokine forward as one of the potential 
disease initiators. The LT-β gene promoter contains κB and TonE sequences, pointing the finger at 
both the NF-κB transcription factor family and NFAT5 as its regulators, with expression of LT-β 
being induced in T-cells both by inflammatory stimuli and NF-κB activation, as well as by osmotic 
stress [19]. 
4.3. Monocyte chemoattractant protein 1 
An important role for the chemoattractant cytokine MCP-1 has been established in the IIM, 
exhibiting disease subgroup-related expression patterns [41]. Cytotoxic T-cells and M1 macrophages 
actively invading nonnecrotic muscle fibers in PM/IBM tissues are strongly MCP-1 positive. 
Specifically in the vicinity of the endomysial inflammatory infiltrates of PM/IBM tissues, the blood 
vessel endothelium is prominently positive for MCP-1. In contrast, endothelial MCP-1 staining is 
more homogeneously distributed in DM, with blood vessels staining strongly also remote from sites 
with perifascicular tissue damage and inflammation. In DM, perimysial inflammatory cell collections 
express lower levels of MCP-1 [42]. Both the NF-κB family and NFAT5 are important inducers of 
MCP-1 expression. In kidney cells, MCP-1 gene expression can be achieved via TNF-α induced  
NF-κB activation, but also by hypertonic conditions [30]. 
4.4. Osmolyte pathways 
NFAT5 not only activates pro-inflammatory cytokines, but in addition regulates the expression 
of protective genes. As one of its main cellular functions, the transcription factor mediates the 
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intracellular accumulation of small organic osmolytes in response to changing osmotic conditions. 
Osmolyte pathway genes contain TonE elements, and include aldose reductase (AKR1B1), taurine 
transporter (SLC6A6), and sodium/myo-inositol cotransporter (SLC5A3), of which only AKR1B1 is 
expressed in high amounts in normal skeletal muscle. In the perifascicular atrophic fibers of DM 
muscle however, strong staining for AKR1B1, SLC6A6 and SLC5A3 is induced [10]. In these fibers, 
upregulation of HSP70 is also present (Figure 1E), a chaperone of the heat shock protein family 
under control of NFAT5 [43]. Also, the related molecular targets MCP1 and iNOS are induced in the 
perifascicular atrophic muscle fibers [10]. But it should be noted that AKR1B1, SLC6A6 and 
SLC5A3 are also induced in the regenerating muscle fibers, possibly as a protective mechanism 
aiding the buildup of the cell’s renewed proteome.  
In addition to an involvement in tissue damage and regeneration, osmolytes have been shown to 
be potent immune regulators. They influence immune cell function and regulate cell volume as an 
important aspect of their phagocytic activity. A subset of macrophages and T-cells infiltrating IIM 
muscle have been shown SLC5A3 positive [10], but SLC6A6 and AKR1B1 could not be detected. If 
a pivotal role in chronic inflammation is played by specific members of the osmolyte pathway, this 
could evolve into an attractive target for therapy. The plausibility of an anti-inflammatory approach 
targeting osmolyte accumulators has already been shown with AKR1B1 inhibitors put forward as a 
novel therapeutic strategy [44]. This seems an amenable approach, as the beneficiary effects of the 
pathway members appear to be based mostly on redundant cytoprotective activities that can be 
compensated when individual partners are targeted. There indeed is a definite need to develop novel 
therapies, as classical broad range immunosuppressive compounds that are most often used to treat 
DM and PM can present with severe side effects. In addition, treating IBM remains a challenge to 
date, as these patients generally do not respond to the available immunomodulatory drugs, and trials 
with immunoregulatory biologicals have generated mostly discouraging results [45].  
5. Conclusions 
From the data gathered so far, it is clear that transcription factor NF-κB and NFAT families are 
both involved in the regulation of muscle tissue protection and damage repair. Both transcription 
factors contribute to myoblast migration and differentiation into functional myotubes, and are 
therefore imperative to muscle regeneration. These transcription factors do, however, also possess 
potent pro-inflammatory properties. In the IIM, the delicate balance between their anabolic and 
catabolic activities seems seriously disturbed and these transcription factors become important 
mediators of the chronic and tissue-damaging inflammatory response. A role for NF-κB in the 
endotheliopathic processes of DM and the cytotoxic muscle fiber damage in PM/IBM, and for both 
NF-κB and NFAT5 in the perifascicular muscle fiber atrophy in DM comes forward. Key cytokines 
in the underlying context-dependent communication between transcription factors seem to be TNF-α, 
LT-β and MCP-1. The expression patterns of these cytokines are indeed reflective of the differential 
targeting displayed in different disease entities: blood vessel and perifascicular damage in case of 
DM on the one hand, and muscle fiber and endomysial damage for PM/IBM on the other hand.  
It is crucial to further unravel signaling and interaction between the pathways in order to gain 
insight into the precise sequence of events responsible for sustained inflammation. Table 1 illustrates 
how limited our knowledge still is on the involvement of the transcription factor families and how 
badly needed proliferation of insight is to help identify novel therapeutic targets for the future. 
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